{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T01:42:24Z","timestamp":1777081344836,"version":"3.51.4"},"reference-count":37,"publisher":"VM Media SP. zo.o VM Group SK","issue":"3","license":[{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurologia i Neurochirurgia Polska"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1016\/j.pjnns.2018.01.007","type":"journal-article","created":{"date-parts":[[2018,2,6]],"date-time":"2018-02-06T02:32:11Z","timestamp":1517884331000},"page":"410-414","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Intraventricular treatment of secondary central nervous system lymphoma \u2013 Case study and literature overview"],"prefix":"10.5603","volume":"52","author":[{"given":"Dariusz","family":"Szczepanek","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ewa","family":"W\u0105sik-Szczepanek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agnieszka","family":"Szymczyk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomasz","family":"Gromek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ewelina","family":"Grywalska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monika","family":"Podhorecka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marek","family":"Hus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3595","reference":[{"key":"10.1016\/j.pjnns.2018.01.007_bib0190","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1532\/IJH97.06091","article-title":"Secondary central nervous system lymphoma","volume":"84","author":"Tomita","year":"2006","journal-title":"Int J Hematol"},{"key":"10.1016\/j.pjnns.2018.01.007_bib0195","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1200\/JCO.2008.16.8021","article-title":"Natural history of CNS relapse in patients with aggressive non-Hodgkin's lymphoma: a 20-year follow-up analysis of SWOG 8516\u2014The Southwest Oncology Group","volume":"27","author":"Bernstein","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.pjnns.2018.01.007_bib0200","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/S1470-2045(15)00076-5","article-title":"Diagnosis and treatment of primary CNS lymphoma in immunocompetent patients: guidelines from the European Association for Neuro-Oncology","volume":"16","author":"Hoang-Xuan","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.pjnns.2018.01.007_bib0205","doi-asserted-by":"crossref","first-page":"5019","DOI":"10.1182\/blood-2011-01-293050","article-title":"The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications","volume":"117","author":"Campo","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.pjnns.2018.01.007_bib0210","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1182\/blood-2014-05-577189","article-title":"Diffuse large B-cell lymphoma: optimizing outcome in the context of clinical and biologic heterogeneity","volume":"125","author":"Sehn","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.pjnns.2018.01.007_bib0215","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/j.1349-7006.2011.02139.x","article-title":"Central nervous system event in patients with diffuse large B-cell lymphoma in the rituximab era","volume":"103","author":"Tomita","year":"2012","journal-title":"Cancer Sci"},{"key":"10.1016\/j.pjnns.2018.01.007_bib0220","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1093\/annonc\/mdp432","article-title":"Incidence and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: the impact of the addition of rituximab to CHOP chemotherapy","volume":"21","author":"Villa","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1016\/j.pjnns.2018.01.007_bib0225","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1093\/annonc\/mdl327","article-title":"Incidence and risk factors of central nervous system recurrence in aggressive lymphoma\u2014a survey of 1693 patients treated in protocol of German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL)","volume":"18","author":"Boehme","year":"2007","journal-title":"Ann Oncol"},{"key":"10.1016\/j.pjnns.2018.01.007_bib0230","doi-asserted-by":"crossref","first-page":"3896","DOI":"10.1182\/blood-2008-10-182253","article-title":"CNS events in elderly patients with aggressive lymphoma treated with modern chemotherapy (CHOP-14) with or without rituximab: an analysis of patients treated in the RICOVER-60 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL)","volume":"113","author":"Boehme","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.pjnns.2018.01.007_bib0235","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1007\/s12185-009-0289-2","article-title":"Diffuse large B-cell lymphoma with central nervous system relapse: prognosis and risk factors according to retrospective analysis from a single centre experience","volume":"89","author":"Shimazu","year":"2009","journal-title":"Int J Hematol"},{"key":"10.1016\/j.pjnns.2018.01.007_bib0240","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1182\/blood-2007-07-101402","article-title":"Brain parenchyma involvement as isolated central nervous system relapse of systemic non-Hodgkin lymphoma: an International Primary CNS Lymphoma Collaborative Group report","volume":"111","author":"Doolittle","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.pjnns.2018.01.007_bib0245","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1182\/blood.V91.4.1178","article-title":"Risk factors, treatment, and outcome of central nervous system recurrence in adults with intermediate-grade and immunoblastic lymphoma","author":"Van Besien","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.pjnns.2018.01.007_bib0250","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1093\/annonc\/mdl434","article-title":"The role of intrathecal chemotherapy prophylaxis in patients with diffuse large B-cell lymphoma","volume":"18","author":"Arkenau","year":"2007","journal-title":"Ann Oncol"},{"key":"10.1016\/j.pjnns.2018.01.007_bib0255","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1182\/blood-2004-05-1982","article-title":"High incidence of occult leptomeningeal disease detected by flow cytometry in newly diagnosed aggressive B-cell lymphomas at risk for central nervous system involvement: the role of flow cytometry versus cytology","volume":"105","author":"Hegde","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.pjnns.2018.01.007_bib0260","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1200\/JCO.2008.17.7089","article-title":"Identification of leptomeningeal disease in aggressive B-cell non-Hodgkin's lymphoma: improved sensitivity of flow cytometry","volume":"27","author":"Quijano","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.pjnns.2018.01.007_bib0265","doi-asserted-by":"crossref","first-page":"2944","DOI":"10.1002\/cncr.26588","article-title":"Lack of benefit of central nervous system prophylaxis for diffuse large B-cell lymphoma in the rituximab era: findings from a large national database","volume":"118","author":"Kumar","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.pjnns.2018.01.007_bib0270","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1093\/annonc\/mdh013","article-title":"Incidence and risk factors for central nervous system occurrence in elderly patients with diffuse large-B-cell lymphoma: influence of rituximab","volume":"15","author":"Feugier","year":"2004","journal-title":"Ann Oncol"},{"key":"10.1016\/j.pjnns.2018.01.007_bib0275","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1200\/JCO.2006.09.7311","article-title":"Phase I study of intraventricular administration of rituximab in patients with recurrent CNS and intraocular lymphoma","volume":"25","author":"Rubenstein","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.pjnns.2018.01.007_bib0280","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1212\/WNL.0b013e31820f2d94","article-title":"Rituximab mono-therapy for patients with recurrent primary CNS lymphoma","volume":"76","author":"Batchelor","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.pjnns.2018.01.007_bib0285","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.clml.2015.02.026","article-title":"Influence of rituximab on central nervous system relapse in diffuse large B-cell lymphoma and role of prophylaxis\u2014a systematic review of prospective studies","author":"Ghose","year":"2015","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.pjnns.2018.01.007_bib0290","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1002\/1097-0142(19800401)45:7<1556::AID-CNCR2820450707>3.0.CO;2-B","article-title":"Successful treatment of recurrent primary central nervous system lymphoma with high-dose methotrexate","volume":"45","author":"Ervin","year":"1980","journal-title":"Cancer"},{"key":"10.1016\/j.pjnns.2018.01.007_bib0295","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1080\/10428190290012092","article-title":"Central nervous system relapse of systemic non-Hodgkin's lymphoma: results of treatment based on high-dose methotrexate combination chemotherapy","volume":"43","author":"Bokstein","year":"2002","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.pjnns.2018.01.007_bib0300","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1007\/s00277-010-1150-7","article-title":"Central nervous system (CNS) relapse in diffuse large B cell lymphoma (DLBCL): pre- and post-rituximab","volume":"90","author":"Tai","year":"2011","journal-title":"Ann Hematol"},{"key":"10.1016\/j.pjnns.2018.01.007_bib0305","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1182\/blood-2012-07-440974","article-title":"Multicenter phase 1 trial of intraventricular immunochemotherapy in recurrent CNS lymphoma","volume":"121","author":"Rubenstein","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.pjnns.2018.01.007_bib0310","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/0360-3016(92)90538-S","article-title":"Non-Hodgkin's lymphoma of the brain: can high dose, large volume radiation therapy improve survival? Report on a prospective trial by the Radiation Therapy Oncology Group (RTOG): RTOG 8315","volume":"23","author":"Nelson","year":"1992","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.pjnns.2018.01.007_bib0315","doi-asserted-by":"crossref","first-page":"364","DOI":"10.3324\/haematol.2012.077917","article-title":"Phase II study of central nervous system (CNS)-directed chemotherapy including high-dose chemotherapy with autologous stem cell transplantation for CNS relapse of aggressive lymphomas","volume":"98","author":"Korfel","year":"2013","journal-title":"Hematologica"},{"key":"10.1016\/j.pjnns.2018.01.007_bib0320","doi-asserted-by":"crossref","first-page":"3903","DOI":"10.1200\/JCO.2015.61.1236","article-title":"High doses of antimetabolites follow by high-dose sequential chemoimmunotherapy and autologous stem-cell transplantation In patients with systemic B-cell lymphoma and secondary CNS involvement: final results of a multicenter phase II trial","volume":"33","author":"Ferrari","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.pjnns.2018.01.007_bib0325","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1002\/cncr.29023","article-title":"Phase II trial of high-dose rituximab with high-dose cytarabine mobilization therapy and high-dose thiotepa, busulfan, and cyclophosphamide (R-TBC) autologous stem cell transplant in patients with CNS involvement by non-Hodgkin lymphoma","volume":"121","author":"Chen","year":"2015","journal-title":"Cancer"},{"key":"10.1016\/j.pjnns.2018.01.007_bib0330","doi-asserted-by":"crossref","first-page":"3072","DOI":"10.1182\/blood-2017-01-764209","article-title":"PD-1 blockade with nivolumab in relaps\/refractory primary central nervous system and testicular lymphoma","volume":"129","author":"Nayak","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.pjnns.2018.01.007_bib0335","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1182\/blood.V128.22.783.783","article-title":"Single-agent ibrutinib in recurrent\/refractory central nervous system lymphoma","volume":"128","author":"Grommes","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.pjnns.2018.01.007_bib0340","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1182\/blood.V128.22.785.785","article-title":"Rituximab-lenalidomide (REVRI) in relapse or refractory primary central nervous system (PCNSL) or vitreo retinal lymphoma (PVRL): results of a \u201cproof of concept\u201d phase II study of the French LOC network","volume":"128","author":"Ghesquieres","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.pjnns.2018.01.007_bib0345","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJMc1704610","article-title":"Anti-CD19 CAR T cells in CNS diffuse large-B-cell lymphoma","volume":"377","author":"Abramson","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pjnns.2018.01.007_bib0350","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/S0001-5814(12)33005-3","article-title":"The efficacy of intraventricular treatment in therapy of primary central nervous system lymphomas","volume":"43","author":"Szczepanek","year":"2012","journal-title":"Acta Haematol"},{"key":"10.1016\/j.pjnns.2018.01.007_bib0355","doi-asserted-by":"crossref","first-page":"4489","DOI":"10.1200\/JCO.2003.04.056","article-title":"Primary central nervous system lymphoma: results of a pilot and phase II study of systemic and intraventricular chemotherapy with deferred radiotherapy","author":"Pels","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.pjnns.2018.01.007_bib0360","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/BF02147089","article-title":"The intracerebral penetration of intraventricularly administered methotrexate: a quantitative autoradiographic study","volume":"7","author":"Grossman","year":"1989","journal-title":"J Neuro-Oncol"},{"key":"10.1016\/j.pjnns.2018.01.007_bib0365","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1200\/JCO.2015.64.9897","article-title":"Phase II trial of temsirolimus for relapsed\/refractory primary CNS lymphoma","volume":"20","author":"Korfel","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.pjnns.2018.01.007_bib0370","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.3109\/10428194.2014.889823","article-title":"Clinical outcomes of patients with newly diagnosed primary central nervous system lymphoma are comparable on treatment with high-dose methotrexate plus temozolomide and with high-dose methotrexate plus cytarabine: a single-institution experience","volume":"55","author":"Wang","year":"2014","journal-title":"Leuk Lymphoma"}],"container-title":["Neurologia i Neurochirurgia Polska"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028384317303109?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028384317303109?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,10,27]],"date-time":"2020-10-27T12:45:45Z","timestamp":1603802745000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028384317303109"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5]]},"references-count":37,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["S0028384317303109"],"URL":"https:\/\/doi.org\/10.1016\/j.pjnns.2018.01.007","relation":{},"ISSN":["0028-3843"],"issn-type":[{"value":"0028-3843","type":"print"}],"subject":[],"published":{"date-parts":[[2018,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Intraventricular treatment of secondary central nervous system lymphoma \u2013 Case study and literature overview","name":"articletitle","label":"Article Title"},{"value":"Neurologia i Neurochirurgia Polska","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pjnns.2018.01.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Polish Neurological Society. Published by Elsevier Sp. z o.o. All rights reserved.","name":"copyright","label":"Copyright"}]}}